Hualan Biological Vaccine Inc. (SHE: 301207)

Hualan Biological Vaccine Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020	Dec 31, 2019
Operating Revenue	2,295	2,409	1,824	1,830	2,425	1,048
Other Revenue	1.74	1.2	1.57	-	1.28	1.33
Revenue	2,296	2,410	1,826	1,830	2,426	1,049
Revenue Growth (YoY)	151.05%	32.03%	-0.23%	-24.59%	131.30%	30.68%
Cost of Revenue	392.28	382.02	369.19	354.01	288.64	210.56
Gross Profit	1,904	2,028	1,456	1,476	2,138	838.43
Selling, General & Admin	1,014	1,019	776.35	647.5	915.27	335.02
Research & Development	86.57	91.11	134.64	144.13	110.94	73.04
Other Operating Expenses	21.99	15.18	12.59	10.84	13.25	7.7
Operating Expenses	1,130	1,146	952.36	803.51	1,083	426.4
Operating Income	774.36	881.98	504.09	672.29	1,055	412.03
Interest Expense	-5.98	-6.08	-10.69	-13.32	-2	-
Interest & Investment Income	85.74	81.93	72.01	28.82	9.4	10.97
Currency Exchange Gain (Loss)	0.1	-0.23	-0.11	0.25	0.23	-
Other Non Operating Income (Expenses)	1.67	-0.15	0.08	-0.19	-0.23	-0.16
EBT Excluding Unusual Items	855.88	957.44	565.37	687.85	1,062	422.85
Gain (Loss) on Sale of Investments	36.45	39.68	16.85	14.25	1.86	4.67
Gain (Loss) on Sale of Assets	-0.36	-0.2	0.63	-	-	-
Asset Writedown	-0.31	-0.25	-0.05	-1	-0.33	-
Other Unusual Items	15.93	10.21	6.68	4.65	10.36	4.56
Pretax Income	907.59	1,007	589.48	705.75	1,074	432.07
Income Tax Expense	130.57	146.91	69.84	84.78	149.14	56.78
Net Income	777.02	859.97	519.63	620.97	924.91	375.3
Net Income to Common	777.02	859.97	519.63	620.97	924.91	375.3
Net Income Growth	135.70%	65.49%	-16.32%	-32.86%	146.45%	38.92%
Shares Outstanding (Basic)	601	601	590	540	540	541
Shares Outstanding (Diluted)	602	602	590	540	540	541
Shares Change (YoY)	0.22%	2.03%	9.33%	0.00%	-0.24%	0.19%
EPS (Basic)	1.29	1.43	0.88	1.15	1.71	0.69
EPS (Diluted)	1.29	1.43	0.88	1.15	1.71	0.69
EPS Growth	135.19%	62.20%	-23.46%	-32.86%	147.05%	38.66%
Free Cash Flow	687.56	825.42	196.01	-66.73	161.43	131.15
Free Cash Flow Per Share	1.14	1.37	0.33	-0.12	0.30	0.24
Dividend Per Share	0.600	0.600	0.200	0.133	-	-
Dividend Growth	200.00%	200.00%	50.04%	-	-	-
Gross Margin	82.92%	84.15%	79.78%	80.65%	88.10%	79.93%
Operating Margin	33.72%	36.59%	27.61%	36.74%	43.47%	39.28%
Profit Margin	33.84%	35.68%	28.46%	33.94%	38.12%	35.78%
Free Cash Flow Margin	29.94%	34.24%	10.74%	-3.65%	6.65%	12.50%
EBITDA	914.1	1,022	638.51	740.2	1,096	744.84
EBITDA Margin	39.81%	42.41%	34.97%	40.45%	45.15%	71.01%
D&A For EBITDA	139.74	140.33	134.42	67.91	40.85	332.81
EBIT	774.36	881.98	504.09	672.29	1,055	412.03
EBIT Margin	33.72%	36.59%	27.61%	36.74%	43.47%	39.28%
Effective Tax Rate	14.39%	14.59%	11.85%	12.01%	13.89%	13.14%
Revenue as Reported	2,296	2,410	1,826	1,830	2,426	1,049
Advertising Expenses	-	-	-	-	-	281.96

Source: S&P Capital IQ. Standard template. Financial Sources.